Deutschland

TUI AG: Statement in response to current press reports with respect to a potential equity raise of TUI AG

Thursday, October 1, 2020 - 10:07pm

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Against the background of current press reports, TUI AG states, in view of the still very volatile market environment resulting from the COVID 19 crisis, it continues evaluating various measures to achieve an optimal balance sheet structure and maturity profile.
  • A decision on whether such a measure will be implemented has not yet been made.

DGAP-News: VARTA AG: Change in the Management Board of VARTA AG

Thursday, October 1, 2020 - 4:10pm

CFO Steffen Munz will step down from his position on the Board of Management at his own request on December 31, 2020

Key Points: 
  • CFO Steffen Munz will step down from his position on the Board of Management at his own request on December 31, 2020
    Armin Hessenberger has been appointed to the management board effective October 01, 2020, and will become new CFO of VARTA AG effective January 01, 2021
    VARTA AG announced changes to the management board today.
  • CFO Steffen Munz will step down from his position on the management board at his own request on December 31, 2020 to pursue other opportunities outside the company.
  • The company thanks Steffen Munz for his very successful work as CFO of VARTA AG.
  • Armin Hessenberger has been appointed to the Board of Management effective October 1, 2020, and will be the new CFO of VARTA AG effective January 1, 2021.

DGAP-News: GRENKE AG: Jens Rönnberg to become interim Deputy Chairman of the Supervisory Board of GRENKE AG

Thursday, October 1, 2020 - 3:10pm

Baden-Baden, October 1, 2020: The Supervisory Board of GRENKE AG has elected Jens Rnnberg as interim Deputy Chairman of the Supervisory Board.

Key Points: 
  • Baden-Baden, October 1, 2020: The Supervisory Board of GRENKE AG has elected Jens Rnnberg as interim Deputy Chairman of the Supervisory Board.
  • Jens Rnnberg is a tax consultant and auditor and has been a member of the Supervisory Board of GRENKE AG since November 2019.
  • He is assuming the office of Deputy Chairman from Wolfgang Grenke, whose Supervisory Board mandate has been suspended since September 21, 2020.
  • The new member of the Audit Committee is the Chairman of the Supervisory Board, Ernst-Moritz Lipp, who is taking over from Wolfgang Grenke on an interim basis.

DGAP-News: Ulrich Scherbel new Chief Operating Officer of AMSilk

Thursday, October 1, 2020 - 2:09pm

Planegg, October 1, 2020 - AMSilk GmbH, the world's first industrial supplier of synthetic silk biopolymers, has appointed Ulrich Scherbel as its new COO as of October 1, 2020.

Key Points: 
  • Planegg, October 1, 2020 - AMSilk GmbH, the world's first industrial supplier of synthetic silk biopolymers, has appointed Ulrich Scherbel as its new COO as of October 1, 2020.
  • Ulrich Scherbel has more than 25 years of expertise in innovative textiles.
  • Regarding his new position at AMSilk Ulrich Scherbel says: "AMSilk's innovative and world-leading biotechnological production method, from plant-based raw materials, creates fascinating silk biopolymers, which not only have unique properties, but are also biodegradable and recyclable.
  • Jens Klein, CEO of AMSilk, adds: "We are very pleased to have Ulrich Scherbel on board as COO.

DGAP-News: Sangui BioTech International Inc.: Sales of USD 28,915 in fiscal year 2020

Thursday, October 1, 2020 - 1:10pm

Hamburg, October, 01, 2020: In the fiscal year 2020 (01/07/2019 to 30/06/2020) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 28,915.

Key Points: 
  • Hamburg, October, 01, 2020: In the fiscal year 2020 (01/07/2019 to 30/06/2020) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 28,915.
  • Due to decreased revenues of the wound spray Granulox, the resulting royalty income of 2020 decreased by 67% compared to previous year.
  • As operating expenses decreased USD 215,327 or 51% to USD 210,309 during the period, operating loss decreased USD 156,241 to USD 181,394 from the prior year.
  • Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI).